Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cannabidiol was ineffective for manic episode of bipolar affective disorder

Full text
Author(s):
Zuardi, A. W. [1] ; Crippa, J. A. S. [1] ; Dursun, S. M. [2] ; Morais, S. L. [1] ; Vilela, J. A. A. [1] ; Sanches, R. F. [1] ; Hallak, J. E. C. [1]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Fac Med, Dept Neuropsychiat & Med Psychol, Sao Paulo - Brazil
[2] Univ Alberta, Dept Psychiat, Edmonton, AB - Canada
Total Affiliations: 2
Document type: Journal article
Source: JOURNAL OF PSYCHOPHARMACOLOGY; v. 24, n. 1, p. 135-137, JAN 2010.
Web of Science Citations: 27
Abstract

The pharmacological profile of cannabidiol (CBD) has several characteristics in common with drugs known to benefit bipolar affective disorder (BAD), leading to the hypothesis that CBD may have therapeutic properties in BAD. Therefore, the aim of the present report was to directly investigate for the first time the efficacy and safety of CBD in two patients with BAD. Both patients met DSM IV criteria for bipolar I disorder experiencing a manic episode without comorbid conditions. This was an inpatient study, and the efficacy, tolerability and side effects were assessed. Both patients received placebo for the initial 5 days and CBD from the 6th to 30th day (initial oral dose of 600 mg reaching 1200 mg/day). From the 6th to the 20th day, the first patient (a 34-year-old woman) received adjunctive olanzapine (oral dose of 10-15 mg). On day 31, CBD treatment was discontinued and replaced by placebo for 5 days. The first patient showed symptoms improvement while on olanzapine plus CBD, but showed no additional improvement during CBD monotherapy. The second patient (a 36-year-old woman) had no symptoms improvement with any dose of CBD during the trial. Both patients tolerated CBD very well and no side-effects were reported. These preliminary data suggest that CBD may not be effective for the manic episode of BAD. (AU)

FAPESP's process: 02/13197-2 - Participation of glutamate and nitric oxide on the pathophysiology of neuropsychiatry disorders
Grantee:Francisco Silveira Guimaraes
Support Opportunities: Research Projects - Thematic Grants